Summary
12.91
-0.40
(-3.01%)
07/16/2026
COMPASS Pathways plc (CMPS)Key Facts
Performance
Historical returns1D
-3.01%
1W
-2.13%
1M
12.89%
3M
123.32%
6M
82.08%
1Y
273.88%
5Y
-61.71%
Snapshot
Key statisticsClose
12.91
Change
-0.40
Change %
-3.01%
Open
14.50
Day Range
12.83 – 14.60
Volume
3,022,629
Avg Vol (20d)
4,125,754
Rel Vol
0.73x
52W Range
3.50 - 15.40
vs 52W High
-16.17%
vs 52W Low
268.86%
Gap
-0.23
Market Cap
USD 536.65M
Beta
2.23
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 0× | -5.35% |
| 1-Month | 7× | -14.33% |
| 3-Month | 12× | -14.33% |
| 6-Month | 13× | -14.33% |
| YTD | 16× | -14.33% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 33× | -14.33% |
| 2-Year | 16× | -14.33% |
| 3-Year | 13× | -14.33% |
| 5-Year | 11× | -73.63% |
| 10-Year | n/a | n/a |
Financial SnapshotFY 2025
Full financialsRevenue
n/a
Net Income
-USD 287.86M
+85.6% YoY
EPS
-3.08
+33.9% YoY
Gross Margin
n/a
Operating Margin
n/a
Net Margin
n/a
EBITDA
-USD 285.60M
Free Cash Flow
-USD 157.24M
ROE
544.7%
ROA
-136.8%
Debt / Equity
-0.40x
net debt -USD 128.68M
Cash & Equiv.
USD 149.61M
Fundamental Ratings
MainC+
RecommendedSell
DCFNeutral
ROEStrong Sell
ROAStrong Sell
Debt/EquityBuy
P/EStrong Sell
P/BNeutral
Latest Earnings
- CMPS reported last earnings on 2026-05-13.
- EPS of $-0.3 vs $-0.45 estimated — surprise $0.15.
- Revenue of $0M vs $0M estimated — surprise $0M.
News
All newsCompass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label...
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could...
CleanSpark shares surge after company secures $6.6B data center lease agreement
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
Compass Pathways NASDAQ: CMPS said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for treatment-resistant depression, as the company works toward a potential U.S. launch in the first half of 2027.
Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission
Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timeline
Compass Pathways plc (NASDAQ:CMPS) on Wednesday reported 26-week results from Part B of its Phase 3 COMP006 trial, reinforcing the rapid and durable efficacy of COMP360, its synthetic psilocybin therapy for treatment-resistant depression (TRD).
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing Phase 3 COMP006 trial of COMP360, a...
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026...
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated...
Compass Pathways Elects Kathleen Tregoning to Board of Directors
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual...
Compass Pathways: A Trip Worth Taking Before The FDA Verdict
COMPASS Pathways (CMPS) is positioned to pioneer COMP360, the first psychedelic drug for treatment-resistant depression (TRD), with expected FDA approval later this year. COMP360 demonstrated primary endpoint success in Phase 3 trials, with potential for less frequent dosing and improved...
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins
Compass Pathways NASDAQ: CMPS executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant depression, while preparing commercially for a potentially accelerated regulatory...
Compass Pathways: Imminent Commercialization Should Provide Further Upside
Compass Pathways is nearing an inflection point, with solid Phase III data and government support pointing towards a likely FDA approval. CMPS is positioned to address the large, underserved treatment-resistant depression market, leveraging regulatory tailwinds and growing psychiatric support for...
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call Transcript
Compass Pathways shares rise on Q1 results, accelerated FDA review
Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed continued regulatory progress for its lead therapy COMP360 in treatment-resistant depression. For the quarter, Compass reported an adjusted loss of $0.30 per share, coming in...